focus -WSS

focus

author：hotspot 2025-10-01 10:52:07 - browse：966

3D dollar signs come out of a prescription drug bottle — coverage from STAT — Adobe

WASHINGTON — Venture capitalists are still pouring money into drug research in spite of Medicare’s new power to negotiate drug prices, according to Congress’ nonpartisan budget experts.

The Inflation Reduction Act includes two measures that directly lower drug prices. Medicare price negotiation is the most controversial of the two. The law gives drugs 9 years on the market before negotiated prices take effect; biologics get 13 years. Drugs are selected for negotiation among the 50 top-selling drugs without generic or biosimilar competition. Medicare will negotiate prices for 10 drugs to start. Up to 60 drugs will be subject to negotiation over the next four years, and up to 20 more drugs every year afterward.

The law also requires drug companies to pay back Medicare when they raise prices on drugs faster than inflation.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： Departing Stanford president retracts two papers

explore

WSS

Apellis safety probe of eye disease drug centers on injection needle

In science, is the line between industry and academia shifting?

In science, is the line between industry and academia shifting?

NYU Langone launches private ChatGPT for its health care data

Lasker Awards 2023: Winners in biomedical research

What Congress can do to address the rural doctor shortage

entertainment

focus

explore

The cancer drug shortage isn’t new — and neither are the solutions

EpiPen alternative approval delay highlights citizen petition issue

23andMe had bad news about my health. I wish a person had delivered it

FDA panel to weigh approval of NurOwn, controversial ALS drug

Medicare proposal to cover medical devices draws a mixed reaction

Why more medical students aren't specializing in primary care

Heart attack and stroke risk calculators need revising

AstraZeneca bets AAV gene therapy will still deliver the goods

Heart attack and stroke risk calculators need revising

Lasker Awards 2023: Winners in biomedical research

leisure time

Microbiome research is starting to find links to chronic diseases

As pharma fights Medicare drug negotiation, hospitals, docs silent

Lasker Awards 2023: Winners in biomedical research

Appeals court upholds limits to abortion pill

How a symptom of dementia informs our understanding of creativity

Readout LOUD podcast: possible new ALS drug, artificial wombs

knowledge

knowledge

explore

entertainment